3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Dexamethasone
69
Lenalidomide
39
daratumumab
37
Bortezomib
33
pomalidomide
30
Specimen Handling
27
Biopsy
25
carfilzomib
24
Calcium Dobesilate
23
Cyclophosphamide
22
Magnetic Resonance Spectroscopy
20
dexamethasone acetate
15
dexamethasone 21-phosphate
15
auricularum
15
isatuximab
13
fludarabine
12
iberdomide
11
talquetamab
10
belantamab mafodotin
10
Melphalan
10
selinexor
9
X-Rays
8
tocilizumab
7
fludarabine phosphate
6
elotuzumab
6
Nuclear Medicine Department, Hospital
5
trametinib
4
pembrolizumab
4
Thalidomide
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hizentra
×
Plasma cell
×
30 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled